We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Affymetrix Clinical Services Laboratory Receives CLIA Certification
News

Affymetrix Clinical Services Laboratory Receives CLIA Certification

Affymetrix Clinical Services Laboratory Receives CLIA Certification
News

Affymetrix Clinical Services Laboratory Receives CLIA Certification

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Affymetrix Clinical Services Laboratory Receives CLIA Certification"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Affymetrix Inc. has announced that the Affymetrix Clinical Services Laboratory (ACSL) successfully passed the State of California survey for CLIA (Clinical Laboratory Improvement Amendments) certification on April 9, 2007.

The State of California inspector gave ACSL permission to begin offering microarray-based molecular diagnostic patient and clinical trial testing services. These services are designed to improve healthcare and help customers develop personalized tests and therapies faster than ever before.

The Affymetrix-owned and -operated laboratory enables clinical and research laboratories, as well as diagnostic and pharmaceutical companies, to incorporate complex molecular tests into clinical practice.

The CLIA certification ensures that all of its processes are standardized to consistently meet federal and Clinical Laboratory Standards Institute (CLSI) guidelines for accuracy, precision, sensitivity, calibration and control. In addition, all of the ACSL assays have been validated for clinical applications to help ensure reproducible results.

ACSL uses the industry-standard GeneChip® microarray platform, which is the only platform to have earned 510(k) clearance from the United States Food and Drug Administration and to have secured the CE mark from the European Union. A team of licensed and board-certified personnel processes all of the samples and manages data to help ensure the highest quality results.

"The Affymetrix GeneChip® System 3000Dx is the first microarray instrumentation system cleared for molecular diagnostic laboratories and it is becoming the platform of choice for clinical trials and clinical care," said Noel Doheny, senior vice president, molecular diagnostics business unit at Affymetrix. "ACSL will further facilitate this broad adoption of array-based diagnostic tests and help make personalized medicine a reality."

Advertisement